Navigation Links
ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule
Date:6/24/2009

LEUVEN, Belgium, June 25 /PRNewswire-FirstCall/ --

- Recruitment on Track for ThromboGenics' Lead Product for the Non-Surgical Treatment of Eye Disease With No Reported Safety Issues

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that its lead product microplasmin, which is in Phase III trials for the treatment of vitreomacular adhesion, is progressing according to schedule. All protocol-specified, interim masked analyses by the independent Data Monitoring Committee (DMC) have been completed. Recruitment is on track and the DMC, having found no safety concerns, has unanimously recommended proceeding without protocol modification.

Microplasmin's Phase III program is referred to as the MIVI-TRUST (Microplasmin for IntraVitreous Injection-Traction Release without Surgical Treatment) program. This program involves two clinical trials, taking place in the United States (TG-MV-006 trial) and Europe and the United States (TG-MV-007 trial). The indication for both of the Phase III microplasmin trials is the non-surgical treatment of focal vitreomacular adhesion.

Focal vitreomacular adhesion is a condition in which the vitreous gel, in the center of the eye, has an abnormally strong adhesion to the retina at the back of the eye. These adhesions can cause vessel and retinal distortion which results in deterioration in the patient's vision. Moreover, vitreomacular adhesion is thought to play a key role in numerous back of the eye conditions such as macular hole formation, and some forms of macular edema. Vitreomacular adhesion is also potentially associated with a much poorer prognosis in certain major eye indications, including diabetic retinopathy and Age-related Macular Degeneration (AMD).

Both of the Phase III studies are mult
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
8. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014  Heated dialogue in recent months about the ... treatments to Gilead,s new hepatitis C drug Harvoni® – ... questioning what it means to put a price on ... And while drug pricing is one of the most ... a general business and ethical standpoint – it is ...
(Date:11/21/2014)... 2014 Clementia Pharmaceuticals, Inc. ... (EMA) has granted Orphan Medicinal Product Designation ... for the treatment of fibrodysplasia ossificans progressiva ... genetic disease characterized by painful, recurrent episodes ... abnormal bone formation. This process, known as ...
(Date:11/21/2014)... Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ... Executive Officer, will be presenting at the 26 th ... Hotel in New York . The formal ... PM ET. In addition, Mr. Krakauer and Jorgen B. ... one-on-one meetings during the day. An audio ...
Breaking Medicine Technology:"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3
... AstraZeneca (NYSE: AZN ) announced today that Judge Joseph ... that the substance patent protecting CRESTOR (RE37,314 – the ,314 patent) is valid ... committed by any Shionogi employee. The court also held the ,314 patent to ... , , ...
... June 29 Dr. Harry J. Guttman, Esq. , Of ... participant at the 2010 Central Regional Meeting of the American Chemical Society ...  The 2010 CeRMACS attracted over 400 participants and focused on small business ... , , ...
Cached Medicine Technology:CRESTOR® Patent Upheld By US Court 2CRESTOR® Patent Upheld By US Court 3Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2
(Date:11/22/2014)... wide variety and complexity of foods served at holiday ... allergies, an expert warns. "Every person is different ... that it can be really difficult to avoid all ... allergy and clinical immunology at Wake Forest Baptist Medical ... you know you have food allergies, caution should overrule ...
(Date:11/22/2014)... 22, 2014 Hastings and Hastings, a ... experience announces providing clients with the option of leaving ... clients a flexible, intuitive and easy to navigate website ... access to Google + allows clients to research the ... a more informed decision when retaining an attorney. Those ...
(Date:11/22/2014)... 2014 Sandbridge Capital, a private ... the consumer brand sector, acquired a minority stake ... used to help fund BackJoy’s global growth and ... its proprietary apparel and footwear lines. Sandbridge Capital ... of Directors. , BackJoy is a high-growth health ...
(Date:11/22/2014)... November 22, 2014 Wright & Schulte ... side-effects lawsuits have been scheduled between October 2016 ... District of Illinois. U.S. District Judge Matthew F. Kennelly, ... Case Management Order (CMO) on November 6, 2014 that ... attorneys to submit documents and other activities in preparation ...
(Date:11/22/2014)... Those air-blown hand dryers in public restrooms may spread ... study suggests. British researchers placed a harmless type ... to simulate poorly washed hands. They then had them ... to dry their hands. The investigators measured airborne ... both types of dryers than around towel dispensers. ...
Breaking Medicine News(10 mins):Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4Health News:Restroom Hand Dryers Spread More Germs Than Paper Towels, Study Finds 2
... PepsiCo (NYSE: PEP ), the world,s second-largest food and beverage company, today announced new global goals in the areas of nutrition, the environment, and workplace practices at ... ... ... ...
... 22 Accident claims solicitors, First Personal Injury, want to see more advice made readily available to parents and pupils about asbestos exposure ... reasons. , ... , , ... ...
... , March 22 InterAction joins other U.S.-based non-governmental organizations (NGOs) in calling for ... sanitation and hygiene (WASH) crisis. World Water Day provides us with an opportunity to ... safe drinking water and basic sanitation. , ... ...
... For Epilepsy Awareness , ... , ... ... NEW YORK , March 22 This week, bakeries across the United States are cooking ...
... ... on-premise and SaaS archiving provider in the market to archive and stub for all ... archiving for all Unix/Linux-based email servers and file servers for NTFS/NFS/NDS/Netware, , ... Salt Lake City, Utah, and ...
... today by Thomson Reuters. The year-over-year increase topped the 2008 rate of 6.1 percent and occurred in a year when the U.S. inflation rate was negative.   , ... , ... ... ...
Cached Medicine News:Health News:PepsiCo Unveils Global Nutrition, Environment and Workplace Goals 2Health News:PepsiCo Unveils Global Nutrition, Environment and Workplace Goals 3Health News:PepsiCo Unveils Global Nutrition, Environment and Workplace Goals 4Health News:PepsiCo Unveils Global Nutrition, Environment and Workplace Goals 5Health News:PepsiCo Unveils Global Nutrition, Environment and Workplace Goals 6Health News:PepsiCo Unveils Global Nutrition, Environment and Workplace Goals 7Health News:First Personal Injury on Asbestos in Schools 2Health News:Global Development Successes Depend on Access to Water 2Health News:Global Development Successes Depend on Access to Water 3Health News:Purple Cupcake Production on the Rise Nationwide 2Health News:Purple Cupcake Production on the Rise Nationwide 3Health News:MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010 2Health News:MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010 3Health News:MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010 4Health News:MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010 5Health News:MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010 6Health News:Employer Healthcare Costs Jump 7.3% in 2009, According to Thomson Reuters Study 2Health News:Employer Healthcare Costs Jump 7.3% in 2009, According to Thomson Reuters Study 3
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
The Trident ceramic acetabular system provides several important benefits and meets greater demands of younger, more active patients....
Optimal solution for normal acetabulum and younger patients....
Medicine Products: